J9348 Naxitamab - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Naxitamab

Brand Name:

Danyelva

Strength:

1mg

HCPCS:

J9348

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

GD2

Oral (Y/N):

No

FDA Approval Year:

2020

FDA Discontinuation Year:

CMS Effective Date:

July 23, 2021

CMS Discontinuation Date:

Status:

In Use